RATIONALE: Only one controlled trial is known that employed aripiprazole for patients with borderline personality disorder (BPD). This 8-week trial found significant changes on most scales of the symptom checklist (SCL-90-R), Hamilton depression rating scale (HDRS), Hamilton anxiety rating scale (HARS), and on all scales of the state-trait anger expression inventory (STAXI). OBJECTIVES, MATERIALS, AND METHODS: To assess the long-term effectiveness of aripiprazole with multifaceted borderline symptomatology, this 18-month follow-up observation with biannual testing was carried out with the same patients from the previous trial (treated with 15-mg aripiprazoledaily, n = 26, 21 female and 5 male patients; previousplacebogroup, n = 26, 22 female and 4 male patients). RESULTS: According to the intent-to-treat principle, significant changes on all scales of the SCL-90-R, HDRS, HARS, and STAXI were observed in the aripiprazole-treated subjects after 18 months. CONCLUSION:Aripiprazole appears to be an effective and relatively safe agent in the long-term treatment of patients with BPD.
RCT Entities:
RATIONALE: Only one controlled trial is known that employed aripiprazole for patients with borderline personality disorder (BPD). This 8-week trial found significant changes on most scales of the symptom checklist (SCL-90-R), Hamilton depression rating scale (HDRS), Hamilton anxiety rating scale (HARS), and on all scales of the state-trait anger expression inventory (STAXI). OBJECTIVES, MATERIALS, AND METHODS: To assess the long-term effectiveness of aripiprazole with multifaceted borderline symptomatology, this 18-month follow-up observation with biannual testing was carried out with the same patients from the previous trial (treated with 15-mg aripiprazole daily, n = 26, 21 female and 5 male patients; previous placebo group, n = 26, 22 female and 4 male patients). RESULTS: According to the intent-to-treat principle, significant changes on all scales of the SCL-90-R, HDRS, HARS, and STAXI were observed in the aripiprazole-treated subjects after 18 months. CONCLUSION:Aripiprazole appears to be an effective and relatively safe agent in the long-term treatment of patients with BPD.
Authors: Kathryn M Connor; Victoria M Payne; Kishore M Gadde; Wei Zhang; Jonathan R T Davidson Journal: J Clin Psychiatry Date: 2005-01 Impact factor: 4.384
Authors: Mary C Zanarini; Anna A Vujanovic; Elizabeth A Parachini; Jennifer L Boulanger; Frances R Frankenburg; John Hennen Journal: J Pers Disord Date: 2003-06
Authors: Steven G Potkin; Anutosh R Saha; Mary J Kujawa; William H Carson; Mirza Ali; Elyse Stock; Joseph Stringfellow; Gary Ingenito; Stephen R Marder Journal: Arch Gen Psychiatry Date: 2003-07
Authors: Paul E Keck; Ronald Marcus; Stavros Tourkodimitris; Mirza Ali; Amy Liebeskind; Anutosh Saha; Gary Ingenito Journal: Am J Psychiatry Date: 2003-09 Impact factor: 18.112
Authors: Siegfried Kasper; Mark N Lerman; Robert D McQuade; Anutosh Saha; William H Carson; Mirza Ali; Donald Archibald; Gary Ingenito; Ronald Marcus; Teresa Pigott Journal: Int J Neuropsychopharmacol Date: 2003-12 Impact factor: 5.176
Authors: Minna Rytilä-Manninen; Sari Fröjd; Henna Haravuori; Nina Lindberg; Mauri Marttunen; Kirsi Kettunen; Sebastian Therman Journal: Child Adolesc Psychiatry Ment Health Date: 2016-07-15 Impact factor: 3.033